CompletedNCT04479852
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Phoenix and 38 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 30, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 319
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04479852
- Official title
Show the full official title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedPhoenix · Little Rock · Rogers
36 more locations
- Garden Grove
- Oakland
- San Diego
- Torrance
- Colorado Springs
- Gainesville
- Jacksonville
- Lauderhill
- Orlando
- Alpharetta
- Atlanta
- Decatur
- Chicago
- Libertyville
- Gaithersburg
- Saint Charles
- Las Vegas
- Berlin
- Cherry Hill
- Marlton
- Brooklyn
- New York
- Staten Island
- Charlotte
- Hickory
- Dayton
- Oklahoma City
- Portland
- Salem
- Allentown
- Memphis
- Austin
- Dallas
- Houston
- Wichita Falls
- Everett
Questions about this study
What did researchers investigate?
Researchers compared SP-624 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Sirtsei Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including SP-624 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
